Sarepta Therapeutics Inc’s recent filing unveils that its Director Wigzell Hans Lennart Rudolf unloaded Company’s shares for reported $1.31 million on Dec 12 ’24. In the deal valued at $124.84 per share,10,500 shares were sold. As a result of this transaction, Wigzell Hans Lennart Rudolf now holds 22,840 shares worth roughly $2.55 million.
Then, Wigzell Hans Lennart Rudolf bought 10,500 shares, generating $1,310,400 in total proceeds.
Before that, Boor Kathryn Jean sold 1,636 shares. Sarepta Therapeutics Inc shares valued at $205,400 were divested by the Director at a price of $125.55 per share. As a result of the transaction, Boor Kathryn Jean now holds 5,880 shares, worth roughly $0.66 million.
Needham reiterated its Sarepta Therapeutics Inc [SRPT] rating to a Buy in a research note published on November 27, 2024; the price target was $202. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late November with a ‘”a Sell”‘ rating. Cantor Fitzgerald also remained covering SRPT and has increased its forecast on November 07, 2024 with a “an Overweight” recommendation from previously “Neutral” rating. Jefferies started covering the stock on October 21, 2024. It rated SRPT as “a Buy”.
Price Performance Review of SRPT
On Friday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock fall -0.26% to $111.82. Over the last five days, the stock has lost -1.67%. Sarepta Therapeutics Inc shares have fallen nearly -8.04% since the year began. Nevertheless, the stocks have fallen -11.54% over the past one year. While a 52-week high of $173.25 was reached on 01/07/25, a 52-week low of $102.15 was recorded on 02/07/25. SMA at 50 days reached $121.70, while 200 days put it at $128.92.
Levels Of Support And Resistance For SRPT Stock
The 24-hour chart illustrates a support level at 110.10, which if violated will result in even more drops to 108.39. On the upside, there is a resistance level at 112.95. A further resistance level may holdings at 114.09. The Relative Strength Index (RSI) on the 14-day chart is 38.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.16%. Stochastics %K at 39.06% indicates the stock is a holding.
How much short interest is there in Sarepta Therapeutics Inc?
A steep rise in short interest was recorded in Sarepta Therapeutics Inc stocks on 2025-01-15, dropping by -0.61 million shares to a total of 4.98 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 5.59 million shares. There was a decline of -12.15%, which implies that there is a negative sentiment for the stock.
